Eosinophilic Esophagitis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap

The Key Eosinophilic Esophagitis Companies in the market include - Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others.

DelveInsight's "Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Eosinophilic Esophagitis, historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Eosinophilic Esophagitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Eosinophilic Esophagitis Market Forecast [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Eosinophilic Esophagitis Market Report:

*
The Eosinophilic Esophagitis market size was valued approximately USD 1,800 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In February 2025, Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotech firm focused on precision local drug delivery, today shared further positive clinical results from its ongoing RESOLVE Phase 1b/2a trial, which is assessing EP-104GI for the treatment of eosinophilic esophagitis (EoE).

*
In December 2024, Holoclara, a biotech firm focused on worm-derived therapies for allergic and autoimmune diseases, has chosen eosinophilic esophagitis (EoE) as the primary indication for its investigational drug, HC002, with plans to expand to other conditions. The company is currently conducting a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of HC002 in healthy adults.

*
In December 2024, Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotech company developing innovative biologics for inflammatory and immunology (I&I) conditions, including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE), has announced the start of dosing healthy volunteers in its clinical trial of APG333. This novel, subcutaneous monoclonal antibody, with a half-life extension, targets thymic stromal lymphopoietin (TSLP) and is initially being evaluated as a treatment for asthma, COPD, and other I&I disorders.

*
In September 2024, Regeneron Pharmaceuticals and Sanofi revealed that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the expanded approval of DUPIXENT (dupilumab) for eosinophilic esophagitis (EoE) in children as young as 1 year old in the European Union. The recommendation applies to children aged 1-11 years who weigh at least 15 kg. A final decision from the European Commission is expected in the coming months.a

*
The US accounted for Eosinophilic Esophagitis for USD 805 million in 2023 and is expected to rise by 2034.

*
In the EU4 and the UK, Germany leads with the largest market size of roughly USD 21 billion, trailed by France and the UK with approximately USD 19 billion and USD 17 billion, respectively. These figures are anticipated to fluctuate throughout the forecast period (2024-2034) due to continued research and development endeavors, potentially resulting in the identification of more efficacious medications and treatments for managing Eosinophilic Esophagitis.

*
In January 2024, The US FDA granted approval for DUPIXENT (dupilumab) to treat pediatric patients between the ages of 1 and 11 years, weighing at least 15 kg, who have eosinophilic esophagitis (EoE). This approval stems from the Phase III EoE KIDS trial, which demonstrated that a higher percentage of children receiving DUPIXENT achieved histological remission compared to those receiving a placebo.

*
There are few approved medications available in the market to treat eosinophilic esophagitis (EoE), including DUPIXENT (dupilumab) and JORVEZA (budesonide).

*
In 2023, the US had the highest number of diagnosed prevalent cases of Eosinophilic Esophagitis in the 7MM, with approximately 445,000 cases. This figure is expected to rise throughout the forecast period.

*
In 2023, Eosinophilic Esophagitis predominantly affected males in the US, with around 290,000 male cases compared to 156,000 female cases.

*
In the 7MM, individuals aged 18 and above were the most impacted by Eosinophilic Esophagitis, with roughly 156,000 cases reported in 2023.

*
Key Eosinophilic Esophagitis Companies: Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others

*
Key Eosinophilic Esophagitis Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, reslizumab, CC-93538, Mesalamine, IRL201104, budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide plus Prevacid, EUR-1100, and others

*
The Eosinophilic Esophagitis epidemiology based on gender analyzed that Eosinophilic Esophagitis affects more males as compared to females

*
The Eosinophilic Esophagitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Eosinophilic Esophagitis pipeline products will significantly revolutionize the Eosinophilic Esophagitis market dynamics.

Eosinophilic Esophagitis Overview

Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition that affects the esophagus, the tube that connects the mouth to the stomach. In EoE, the esophagus becomes inflamed due to an allergic reaction to certain foods, environmental allergens, or other triggers. This inflammation leads to the accumulation of eosinophils, a type of white blood cell, in the esophageal tissue, causing symptoms such as difficulty swallowing, chest pain, food impaction, and heartburn.

Get a Free sample for the Eosinophilic Esophagitis Market Report:

https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market [https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Eosinophilic Esophagitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Eosinophilic Esophagitis Epidemiology Segmentation:

The Eosinophilic Esophagitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Eosinophilic Esophagitis

*
Prevalent Cases of Eosinophilic Esophagitis by severity

*
Gender-specific Prevalence of Eosinophilic Esophagitis

*
Diagnosed Cases of Episodic and Chronic Eosinophilic Esophagitis

Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ Eosinophilic Esophagitis Epidemiology Forecast [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Eosinophilic Esophagitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Esophagitis market or expected to get launched during the study period. The analysis covers Eosinophilic Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Eosinophilic Esophagitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Eosinophilic Esophagitis Therapies and Key Companies

*
Dupilumab: Regeneron Pharmaceuticals/Sanofi

*
Cendakimab: Bristol-Myers Squibb

*
APT-1011: Ellodi Pharmaceuticals

*
Benralizumab: AstraZeneca

*
Lirentelimab: Allakos

*
ESO-101: EsoCap AG

*
Etrasimod: Pfizer

*
reslizumab: Ception Therapeutics

*
CC-93538: Celgene

*
Mesalamine: Dr. Falk Pharma GmbH

*
IRL201104: Revolo Biotherapeutics

*
budesonide: Shire

*
QAX576: Novartis

*
Florence: EMS

*
RPC4046: Celgene

*
OC000459: Oxagen Ltd

*
Budesonide plus Prevacid: Meritage Pharma, Inc

*
EUR-1100: Forest Laboratories

Discover more about therapies set to grab major Eosinophilic Esophagitis market share @ Eosinophilic Esophagitis Treatment Market [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Eosinophilic Esophagitis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Eosinophilic Esophagitis Companies: Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others

*
Key Eosinophilic Esophagitis Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, reslizumab, CC-93538, Mesalamine, IRL201104, budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide plus Prevacid, EUR-1100, and others

*
Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies

*
Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Eosinophilic Esophagitis Unmet Needs, KOL's views, Analyst's views, Eosinophilic Esophagitis Market Access and Reimbursement

To know more about Eosinophilic Esophagitis companies working in the treatment market, visit @ Eosinophilic Esophagitis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Eosinophilic Esophagitis Market Report Introduction

2. Executive Summary for Eosinophilic Esophagitis

3. SWOT analysis of Eosinophilic Esophagitis

4. Eosinophilic Esophagitis Patient Share (%) Overview at a Glance

5. Eosinophilic Esophagitis Market Overview at a Glance

6. Eosinophilic Esophagitis Disease Background and Overview

7. Eosinophilic Esophagitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Eosinophilic Esophagitis

9. Eosinophilic Esophagitis Current Treatment and Medical Practices

10. Eosinophilic Esophagitis Unmet Needs

11. Eosinophilic Esophagitis Emerging Therapies

12. Eosinophilic Esophagitis Market Outlook

13. Country-Wise Eosinophilic Esophagitis Market Analysis (2020-2034)

14. Eosinophilic Esophagitis Market Access and Reimbursement of Therapies

15. Eosinophilic Esophagitis Market Drivers

16. Eosinophilic Esophagitis Market Barriers

17. Eosinophilic Esophagitis Appendix

18. Eosinophilic Esophagitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-esophagitis-market-anticipated-to-expand-rapidly-during-20242034-says-delveinsight-regeneron-pharmaceuticals-sanofi-bristolmyers-squibb-ellodi-pharma-astrazeneca-allakos-esocap]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.